Maximizing Rare Disease Drug Development with Orphan and Breakthrough Designations

Introduction: Strategic Use of Dual Designations

Rare disease therapies face considerable scientific and logistical challenges due to limited patient populations, fragmented natural history data, and evolving regulatory expectations. Fortunately, the FDA and other global regulators offer specific incentive programs such as Orphan Drug Designation (ODD) and Breakthrough Therapy (BT) to facilitate faster development and review. When used together, these designations can create a powerful framework for expediting approval and maximizing regulatory support.

This tutorial explains how combining ODD and BT designations can offer significant advantages, while also highlighting the complexities sponsors must manage when applying both pathways.

What Is Orphan Drug Designation (ODD)?

The Orphan Drug Designation is granted by the FDA to drugs and biologics intended for the treatment, diagnosis, or prevention of rare diseases affecting fewer than 200,000 people in the U.S. Benefits of ODD include:

• 7 years of marketing exclusivity upon approval
• Tax credits up to 25% of qualified clinical trial costs
• Waiver of Prescription Drug User Fee Act (PDUFA) fees
• Access to FDA Orphan Products Grant Program

In the EU, the European Medicines Agency (EMA) offers similar incentives, including 10-year market exclusivity and protocol assistance.

What Is Breakthrough Therapy Designation (BTD)?

Breakthrough Therapy Designation is granted when preliminary clinical evidence suggests the drug may offer substantial improvement over existing therapies on clinically significant endpoints. Benefits of BTD include:

• Frequent FDA interactions (e.g., Type B and C meetings)
• Priority review eligibility
• Rolling submission of New Drug Application (NDA) or Biologics License Application (BLA)
• Organizational commitment with senior FDA reviewers

BTD focuses on clinical promise and speed, while ODD focuses on public health need and rarity. Many rare disease therapies meet the criteria for both.

Opportunities of Combining ODD and BTD

Sponsors that secure both ODD and BTD can benefit from a synergistic regulatory pathway that accelerates development and enhances product value. Advantages include:

• Early engagement with regulators: BTD enables deep collaboration on trial design and endpoints
• Financial incentives: Tax credits from ODD reduce development costs
• Commercial protection: 7-year exclusivity under ODD discourages competitors
• Streamlined reviews: Priority review under BTD shortens time to market

Many successful rare disease drugs, such as Spinraza and Zolgensma, were developed under both designations.

Challenges in Managing Dual Designation Pathways

While the combined designations offer numerous advantages, they also introduce complexity in regulatory strategy. Challenges include:

• Coordinating timelines and submissions across both programs
• Meeting high evidentiary standards for Breakthrough eligibility
• Managing post-approval commitments, especially for surrogate endpoints
• Maintaining consistent regulatory engagement across CDER and CBER divisions

Failure to meet expectations under one designation may affect continued support under the other. Strategic alignment is key to avoid fragmented communication or development delays.

Regulatory Examples: Case Studies of Dual Designation

Several therapies have successfully combined ODD and BTD, demonstrating the impact of a dual designation strategy:

• Evrysdi (risdiplam): Approved for spinal muscular atrophy with both BTD and ODD, using patient-centric trial designs and rolling NDA submission.
• Trikafta: Triple-combination CF therapy approved with strong regulatory support and rapid Phase 3 progression.
• Lumakras (sotorasib): Though not ODD, its expedited pathway provides parallels in managing Breakthrough and fast track strategies.

More case references can be found at EU Clinical Trials Register.

Best Practices for Applying for Dual Designation

To maximize the benefits of both Orphan Drug Designation and Breakthrough Therapy Designation, sponsors must plan their regulatory strategy early. Here are some key recommendations:

• Initiate Orphan Drug Designation Early: Apply as soon as preclinical or early clinical data justifies the indication’s rarity and unmet need. It’s ideal to secure ODD before the IND or early Phase I trials.
• Leverage Strong Early Clinical Evidence for BTD: Apply for BTD when interim clinical results show substantial improvement over available therapies. This typically occurs during or after Phase II.
• Align Regulatory and Clinical Teams: Coordinate submissions to ensure consistency in messaging, data interpretation, and endpoint selection.
• Engage in Type B and Type C Meetings: These discussions provide clarity on expectations, potential challenges, and opportunities for acceleration.

Proper sequencing and documentation are critical for success when managing multiple designation applications.

Navigating FDA Interactions for ODD and BTD

The FDA encourages frequent engagement for sponsors with BTD products. These interactions can include:

• Pre-IND and End-of-Phase meetings
• Advice on protocol design, endpoint selection, and statistical plans
• Support for rolling submission components (e.g., CMC, nonclinical)

For sponsors with ODD, these interactions often focus on the natural history of the disease, appropriateness of clinical endpoints, and justification of trial design. When both designations are in place, the regulatory feedback becomes more dynamic and responsive.

EMA Approach to Dual Designation Strategies

In the European Union, the EMA offers orphan designation through the Committee for Orphan Medicinal Products (COMP) and PRIME (PRIority MEdicines) for breakthrough-type development. While these programs differ slightly from FDA equivalents, they serve similar purposes:

• Orphan Designation (EU): Requires prevalence <5 in 10,000 and significant benefit over existing therapies.
• PRIME: Designed to enhance support for innovative medicines targeting unmet needs, including accelerated assessment and scientific advice.

Sponsors can benefit from parallel scientific advice between FDA and EMA, particularly in harmonizing global development plans.

Labeling, Exclusivity, and Commercial Impact

The benefits of combined designations extend beyond development and into market positioning:

• Exclusivity: 7 years in the U.S. and 10 years in the EU prevent generic competition
• Pricing Power: High unmet need and orphan status may support premium pricing models
• Investor Confidence: Regulatory designations signal credibility and potential for return on investment
• Access to Vouchers: In the U.S., Priority Review Vouchers (PRVs) may apply for pediatric rare disease drugs

These benefits should be factored into the long-term commercial and lifecycle planning of the product.

Common Pitfalls in Dual Designation Execution

Sponsors often face challenges in execution, including:

• Submitting underdeveloped applications with weak data
• Inconsistent regulatory narratives across submissions
• Delays in meeting post-approval requirements
• Assuming BTD guarantees approval—it does not

To avoid these pitfalls, companies should engage experienced regulatory strategists and consider early regulatory consultation (e.g., INTERACT meetings with FDA for novel products).

Checklist: Is Your Product a Good Candidate for Dual Designation?

Meeting these criteria suggests a strong candidate for ODD + BTD regulatory strategy.

Conclusion: A Coordinated Path to Success in Rare Disease Development

Combining Orphan Drug Designation and Breakthrough Therapy status can dramatically accelerate drug development timelines, de-risk regulatory reviews, and boost the commercial viability of rare disease therapies.

However, success depends on a strategic, integrated approach to data generation, regulatory engagement, and global alignment. Sponsors must be prepared for continuous dialogue with regulators and fulfill the responsibilities associated with each designation.

With careful planning and execution, dual designations offer an unparalleled opportunity to bring transformative treatments to rare disease patients faster than ever before.

Case Study: Navigating the Orphan Drug Pathway for Successful Approval

Background: Understanding the Orphan Drug Pathway

The Orphan Drug Act (1983) in the U.S. and corresponding regulations in the EU were created to incentivize the development of therapies for rare diseases—conditions affecting fewer than 200,000 individuals in the U.S. or fewer than 5 in 10,000 in the EU. Regulatory incentives such as market exclusivity, tax credits, fee waivers, and grants make the orphan drug pathway an essential regulatory strategy for biotech firms targeting rare and ultra-rare conditions.

This case study explores the journey of Strensiq (asfotase alfa), a recombinant enzyme replacement therapy developed for hypophosphatasia (HPP), a rare, inherited metabolic disorder. Its approval story illustrates how orphan designation can support successful drug development despite small population challenges.

Disease Overview: Hypophosphatasia (HPP)

HPP is an ultra-rare disorder characterized by defective bone mineralization due to mutations in the ALPL gene. Clinical presentations vary widely, from perinatal lethal forms to milder adult-onset forms. Before Strensiq, no approved treatments existed for severe pediatric-onset HPP, making it a textbook case of high unmet medical need.

Patients suffer from respiratory failure, seizures, skeletal deformities, and high mortality in infancy. The rarity of the disease (estimated at 1 in 100,000 live births) and its severity made it a strong candidate for orphan drug development.

Development Milestones and Orphan Designation

Alexion Pharmaceuticals pursued an orphan designation early in development:

• FDA Orphan Designation: Received in 2008
• EMA Orphan Designation: Granted in 2008
• Breakthrough Therapy Designation: Awarded by FDA in 2013

The company leveraged compassionate use programs and patient registries to collect longitudinal natural history and biomarker data. Early trials focused on improving serum alkaline phosphatase levels, growth velocity, and radiographic skeletal improvements, which served as surrogate endpoints.

Trial Design: Using Adaptive and Ethical Approaches

Given the ultra-rare nature and ethical considerations, randomized controlled trials were not feasible. Instead, the sponsor adopted a single-arm, open-label design with historical controls. Primary endpoints included:

• Radiographic Global Impression of Change (RGI-C)
• Growth velocity over 48 weeks
• Improved respiratory function

While the sample size was small (n = 11–20 across studies), the consistency of clinical improvement and survival was sufficient to demonstrate clinical benefit under the FDA Accelerated Approval framework.

Approval Timeline and Regulatory Interactions

The timeline of development demonstrates how expedited pathways reduce delays:

Both agencies emphasized the need for post-marketing data collection and long-term outcome validation. Strensiq also qualified for 7-year market exclusivity in the U.S. and 10 years in the EU.

Additional case study resources available at the Japan RCT Portal.

Key Regulatory Levers That Facilitated Approval

This approval case succeeded due to a blend of:

• Early orphan designation: Unlocking incentives like protocol assistance, tax credits, and reduced fees
• Adaptive trial design: Using real-world data and historical controls to supplement limited sample size
• Close regulatory dialogue: Through Breakthrough and Scientific Advice programs
• Flexible endpoints: Leveraging surrogate markers tied to biological plausibility and natural history

The regulator’s willingness to accept alternative endpoints played a vital role. Without randomized comparative data, the strength of biologic plausibility and patient-reported outcomes (PROs) became essential pillars.

Post-Marketing Commitments and Real-World Evidence (RWE)

Following approval, Alexion committed to:

• Maintaining a global patient registry for long-term follow-up
• Conducting Phase IV studies in adult-onset HPP
• Reporting safety data through periodic safety update reports (PSURs)

The RWE generated from these initiatives further validated the clinical utility of Strensiq in broader patient populations.

Impact on the Rare Disease Ecosystem

This case became a precedent for future rare disease drug developers. It demonstrated that:

• Well-designed, small trials can lead to approval when supported by strong natural history and mechanistic rationale
• Regulatory flexibility is achievable with transparent, high-quality engagement
• Orphan pathway incentives can offset the high development costs associated with rare conditions

It also empowered patient advocacy groups to become more active in trial design and data collection.

Lessons for Sponsors Pursuing the Orphan Pathway

Key takeaways from the Strensiq approval include:

• Start early: File for orphan designation during preclinical development
• Engage with agencies: Use pre-IND, scientific advice, and protocol assistance meetings
• Leverage registries: Build natural history data alongside development
• Plan for lifecycle: Include follow-up indications and global expansion

Integrating regulatory, clinical, and patient engagement strategies from the outset can de-risk rare disease programs substantially.

Conclusion: A Blueprint for Rare Disease Drug Development

The Strensiq case exemplifies how leveraging the orphan drug pathway, creative trial design, and early regulatory engagement can lead to successful market entry—even for ultra-rare conditions. This model holds powerful lessons for biotechs and pharma companies aiming to serve neglected patient populations. With the right strategy, data, and communication, regulatory success in rare diseases is attainable and impactful.